Daratumumab has been demonstrated to reduce aPL titers and treat APS patients that are refractory to first-line anticoagulant therapy, with the Daratumumab in Primary Antiphospholipid Syndrome (DARE-APS) trial launched in 2023 to study the use of daratumumab in primary APS patients [17,18]. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.